Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:vaccine
|
| gptkbp:approvedBy |
gptkb:FDA
hepatitis B vaccine |
| gptkbp:CASNumber |
1413969-25-3
|
| gptkbp:clinicalTrialPhase |
phase 3
|
| gptkbp:composition |
22-mer oligonucleotide
|
| gptkbp:contains |
unmethylated CpG motifs
synthetic oligodeoxynucleotide |
| gptkbp:developedBy |
gptkb:Dynavax_Technologies
|
| gptkbp:effect |
enhances immune response
induces Th1-biased immune response |
| gptkbp:mechanismOfAction |
TLR9 agonist
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:target |
human TLR9
|
| gptkbp:usedIn |
COVID-19 vaccine candidates
VLA2001 HEPLISAV-B SCB-2019 vaccine adjuvanted protein subunit vaccines |
| gptkbp:bfsParent |
gptkb:MVC-COV1901
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
CpG 1018
|